MoneyWorks4Me

Lyka Labs - Quaterly Results

26 May 2025 Evaluate
The Revenue for the quarter ended  March 2025 of Rs. 305.17 millions grew by 13.09 % from Rs. 269.84 millions.The Total Profit for the quarter ended March 2025 of Rs. 13.07 millions grew from Rs.-16.22 millionsOperating profit for the quarter ended March 2025 rose to 41.30 millions as compared to 26.05 millions of corresponding quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 305.17 269.84 13.09 1346.97 1063.96 26.60 1346.97 1063.96 26.60
Other Income 7.20 3.90 84.62 23.44 16.47 42.32 23.44 16.47 42.32
PBIDT 41.30 26.05 58.54 202.32 162.07 24.83 202.32 162.07 24.83
Interest 5.20 10.35 -49.76 23.04 47.98 -51.98 23.04 47.98 -51.98
PBDT 36.10 15.60 131.41 179.28 113.54 57.90 179.28 113.54 57.90
Depreciation 13.38 27.72 -51.73 64.53 122.87 -47.48 64.53 122.87 -47.48
PBT 22.72 -12.12 -287.46 114.75 -9.33 -1329.90 114.75 -9.33 -1329.90
TAX 9.65 4.10 135.37 32.47 13.37 142.86 32.47 13.37 142.86
Deferred Tax 3.45 0.55 527.27 5.23 -2.63 -298.86 5.23 -2.63 -298.86
PAT 13.07 -16.22 -180.58 82.28 -22.70 -462.47 82.28 -22.70 -462.47
Equity 356.90 330.90 7.86 356.90 330.90 7.86 356.90 330.90 7.86
PBIDTM(%) 13.53 9.65 40.19 15.02 15.23 -1.39 15.02 15.23 -1.39
Peers
Company Name CMP
Sun Pharma. Inds. 1850.00
Dr. Reddys Labs. 1202.70
Cipla 1399.90
Lupin 2094.45
Zydus Lifesciences 1184.75
View more..